Cost-Effectiveness Analyses of Hepatitis A Vaccine

@article{Anonychuk2012CostEffectivenessAO,
  title={Cost-Effectiveness Analyses of Hepatitis A Vaccine},
  author={Andrea M. Anonychuk and Andrea C. Tricco and Chris T. Bauch and Ba' Pham and Vladimir Gilca and Bernard Duval and Ava A John-Baptiste and Gloria Woo and Murray Krahn},
  journal={PharmacoEconomics},
  year={2012},
  volume={26},
  pages={17-32}
}
Cost-effectiveness/cost-utility studies of hepatitis A vaccine were identified via a series of literature searches (MEDLINE, EMBASE, HSTAR and SSCI). Citations and full-text articles were reviewed independently by two reviewers. Reference searching, author searches and expert consultation ensured literature saturation. Incremental cost-effectiveness ratios (ICERs) were abstracted for base-case analyses, converted to $US, year 2005 values, and categorised to reflect various levels of cost… Expand
Is vaccination good value for money? A review of cost-utility analyses of vaccination strategies in eight european countries
TLDR
The published literature has shown that vaccination strategies are generally cost-effective in European countries, and high heterogeneity in the results among studies and countries was found. Expand
Quality Assessment in Systematic Reviews: A Literature Review of Health Economic Evaluation of Hepatitis Studies
TLDR
PRISMA was proved to be an effective instrument due to its important role in assessing included reviews and the number of studies which was really carried out based on PRISMA is modest. Expand
Economic evaluations of hepatitis A vaccination in middle-income countries
TLDR
It is found that vaccine price, medical costs, incidence and discount rate were the most influential parameters on the sensitivity analyses and it is argued that further economic evaluations in MICs are still required in the near future. Expand
Cost-effectiveness of hepatitis A vaccination for adults in Belgium.
TLDR
The results indicated that these expanded vaccination strategies are not cost-effective in the epidemiological circumstances of a typical low-endemic western country. Expand
Methodological reviews of economic evaluations in health care: what do they target?
TLDR
The aim of this study is to analyze the methodological characteristics of the reviews of economic evaluations in health care, published during the period 1990–2010, to identify their main features and the potential missing elements. Expand
Hepatitis A immunisation in persons not previously exposed to hepatitis A.
TLDR
The risk of both non-serious local and systemic adverse events was comparable to placebo for the inactivated HAV vaccines, and the clinical effectiveness of both inactivated and live attenuated HAV vaccine was confirmed. Expand
Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach
TLDR
A vaccination program covering one-year old children is projected to be a cost-saving intervention that will significantly reduce the public health and economic burden of hepatitis A in Jordan. Expand
Considerations on the Current Universal Vaccination Policy against Hepatitis A in Greece after Recent Outbreaks
TLDR
Data suggest that universal vaccination may need to be re-considered in Greece and that a more cost effective approach would be to implement a program that will include: a) vaccination of high risk groups, b) universal vaccination of Roma children and improving conditions at Roma camps, c) education of the population and travel advice, and d) enhancement of the control measures to increase safety of shellfish and other foods. Expand
Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic.
TLDR
Estimating the effects of therapeutic treatment with antiviral (AV) drugs during an influenza pandemic in the Netherlands focuses on the sensitivity of the cost-effectiveness ratios to model choice, to the assumed drug coverage, and to the value of several epidemiological factors. Expand
Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review.
TLDR
The Review supports the need to reconsider specific prevention and control measures, to further decrease HAV circulation while providing protection against the infection in the EU and EEA, and could be used to inform susceptible travellers visiting EU andEEA countries with different HAV endemicity levels. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 99 REFERENCES
Cost-effectiveness of hepatitis A vaccination in healthcare workers.
TLDR
For routine vaccination of medical students to be cost-saving, the incidence rate for hepatitis A must be at least 10 times higher than the rate presently reported for the general population. Expand
Cost‐effectiveness analysis of hepatitis A vaccination strategies for adults
TLDR
A decision model simulating costs and health consequences for otherwise healthy adults with respect to hepatitis A prevention concluded that under baseline conditions, neither the “test” nor the ‘vaccination’ strategies are considered cost‐effective according to current standards. Expand
The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States.
TLDR
Targeted vaccination for hepatitis A in patients with chronic hepatitis C may be a cost-effective strategy to decrease the morbidity and mortality associated with hepatitis A superinfection. Expand
Cost-utility of universal hepatitis A vaccination in Canada.
TLDR
A range of possible universal vaccination strategies over an 80-year time horizon is assessed using multiple cost perspectives, and net benefit from the payer perspective is sensitive to the marginal cost of HA/HB vaccine relative to HB vaccine. Expand
The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A.
TLDR
Hepatitis A vaccination of chronic hepatitis C patients would substantially reduce morbidity and mortality in all age groups examined, and cost-effectiveness is most favorable for younger patients. Expand
Cost Effectiveness of Hepatitis A Prevention in France
TLDR
A spreadsheet simulation model of hepatitis A disease was developed to evaluate the cost effectiveness of a recombinant hepatitis A vaccine (‘Havrix’, SmithKline Beecham) in high risk groups in France and suggested that screening before vaccination would be about half as costly as systematic vaccination. Expand
Bias in published cost effectiveness studies: systematic review
TLDR
Most published analyses report favourable incremental cost effectiveness ratios, and studies of higher methodological quality and those conducted in Europe and the US rather than elsewhere were less likely to report ratios below $20 000/QALY. Expand
Cost-Effectiveness of Hepatitis A/B Vaccine versus Hepatitis B Vaccine in Public Sexually Transmitted Disease Clinics
Background Many patients seen at U.S. sexually transmitted disease (STD) clinics are offered hepatitis B vaccination. Substituting hepatitis A/B vaccine would provide additional protection butExpand
Cost-effectiveness analysis of hepatitis A prevention in travellers.
TLDR
A decision-tree-based model enables the calculation of expected costs and expected numbers of hepatitis A virus HAV infections based on different intervention strategies and it seems safe to conclude that vaccination is more cost-effective than the currently recommended passive immunization with immunoglobulin. Expand
Cost Effectiveness of Hepatitis A Virus Immunisation in Spain
TLDR
Evaluated, in economic terms, the recently launched hepatitis A vaccine in comparison with the use of nonspecific immune globulin, is the most efficient alternative; for occasional travellers, and those travelling for periods of under 6 months in 10 years, passive immunisation is more efficient. Expand
...
1
2
3
4
5
...